Partnering to bring your Cell and Gene therapies to life...
Time is of essence in clinical development of new therapies, and manufacturing is often a real bottleneck for gene therapy products. At Yposkesi, we have one of the largest AAV (Adeno-Associated Virus) and lentiviral vector production capacities in Europe. Our growing cGMP facilities, dedicated manpower and expertise allow us to easily accommodate new projects and meet the timeline and budget for your breaking ground in therapeutic treatments.
Yposkesi is a one-stop-shop with both technical expertise and a long-term commitment to quality.
Our services encompass process development, cGMP manufacturing of AAV and lentiviral vectors, Fill&Finish, QC, QA and regulatory support. We aim to establish an open and trustworthy relationship with you with the ultimate goal reducing time-to-market and ensuring an uninterrupted supply of viral vectors.
There is a significant industrial challenge to overcome the manufacturing costs of gene therapy products.
As a leading Contract Development Manufacturing Organization (CDMO), Yposkesi is at the forefront of designing new techniques that improve process robustness and scalability, thereby increasing productivity. We have a highly-skilled and dedicated innovation team focused on your evolving needs and requirements for a committed, sustainable and competitive AAV and lentiviral vector supplier.
Who we are
Yposkesi, an SK pharmteco company, is one of Europe’s largest Contract Development and Manufacturing Organizations (CDMO) for gene therapy viral vector manufacturing.
A one-stop shop for biotech and pharmaceutical companies seeking to advance clinical trials and commercialize new Advanced Therapy Medicinal Products (ATMPs), Yposkesi offers a full range of services in lentiviral vectors and AAV (Adeno-Associated Virus) cGMP manufacturing. Within its current 50,000 sq ft. (approx. 5,000 m2) facility, Yposkesi operates multiple manufacturing suites for bulk drug substance (up to 1,000 L) and fill and finish to support the growing demand for late-phase projects. In 2023, Yposkesi will bring online additional capacity by increasing its global footprint to 100,000 sq ft. (approx. 10,000 m2) with a second large-scale facility designed for EMA and FDA compliance.
Yposkesi’s investment in innovation ensures that its bioprocessing platforms deliver high quality gene-modified cell therapies and in vivo gene therapy projects.
Yposkesi’s staff of ~200 employees is located on the Genopole Campus in Corbeil-Essonnes (South of Paris), France.
Bioprocess development (USP & DSP)
We use innovation to reach new heights in production efficiency.Discover
GMP manufacturing of clinical and commercial viral vector batches
Our extensive AAV and lentiviral vector manufacturing capacity helps ensure on-time deliver.Learn more
Analytical development, assays qualification & validation
Our experts aim to satisfy all your analytical needs with high quality.Discover
Fill & Finish
We offer two options for Fill&Finish: Crystal® Closed Vial Technology or glass vials.Learn more
We provide strategic, technical and regulatory support.Discover